Cost-effectiveness of cetuximab in metastatic colorectal cancer
Links shared publicly online about this topic.
- 1,839total visits
Cost-effectiveness of cetuximab in metastatic colorectal cancer
View full resource at physorg.com
Tags: Cancer, Rectal Cancer, Colon Cancer, Drug, Genes, Erbitux
Most Recently Shared on August 8, 2009 at 10:10 am By:
Cost-effectiveness of cetuximab in metastatic colorectal cancer http://bit.ly/14eL6k
Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer
news-medical.net — “Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that the first patient has been treated in a Phase 1/2 clinical trial of JX-594 in patients with metastatic colorectal cancer who have become refractory to chemotherapy and are either refractory to or ineligible for cetuximab.” View full resource at news-medical.net
Most Recently Shared on March 20, 2012 at 3:46 pm By:
News-Medical.Net Oncology and Health News
Oncology News: Jennerex initiates JX-594 plus irinotecan Phase 1/2 trial in metastatic colorectal cancer: Jenner... http://t.co/MlO8mmVx
Resectability With Cetuximab Extends Life In Difficult-to-Treat Metastatic Colorectal Cancer
medicalnewstoday.com — “Combining the epidermal growth factor receptor (EGFR) inhibitor cetuximab with conventional chemotherapy improves survival in patients who have had complete resection of colorectal liver metastase” View full resource at medicalnewstoday.com
Most Recently Shared on October 7, 2011 at 3:05 pm By:
Resectability With Cetuximab Extends Life In Difficult-to-Treat Metastatic Colorectal Cancer http://mnt.to/429C #healthnews
Oncology Article | Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients
mdlinx.com — “Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients” View full resource at mdlinx.com
Most Recently Shared on September 29, 2011 at 6:22 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patien... http://t.co/iJGjQA9F #oncology
Oncology Article | Colorectal Neoplasms
mdlinx.com — “Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status” View full resource at mdlinx.com
Most Recently Shared on June 29, 2011 at 11:08 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory... http://bit.ly/lUHO2F #oncology
Addition of Dalotuzumab to Cetuximab + Irinotecan Does Not Improve Progression-Free Survival in Colorectal Cancer - ONA
oncologynurseadvisor.com — “The addition of dalotuzumab (MK-0646) to cetuximab and irinotecan failed to improve progression-free survival and overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer, according to study investigators at the American Society of Clinical Oncology’s 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 2:49 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Addition of Dalotuzumab to Cetuximab + Irinotecan Does Not Improve Progression-Free Survival… http://goo.gl/fb/hPz1U
Gastroenterology Article | Colorectal Neoplasms
mdlinx.com — “Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis” View full resource at mdlinx.com
Most Recently Shared on May 4, 2011 at 10:35 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal... http://bit.ly/iSQZox #GI
Oncology Article | Colorectal Neoplasms
mdlinx.com — “Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status” View full resource at mdlinx.com
Most Recently Shared on April 22, 2011 at 9:43 am By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorec... http://bit.ly/en0nRa #oncology
Physician Assistant Article | Colorectal Neoplasms
mdlinx.com — “Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status” View full resource at mdlinx.com
Most Recently Shared on April 21, 2011 at 9:51 pm By:
Raymond DuBois Internist, Gastroenterologist, Health Executive, Physician, and Doctor
Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Status : http://tinyurl.com/42oxqxz
Internal Medicine Article | Colorectal Neoplasms
mdlinx.com — “Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status” View full resource at mdlinx.com
Most Recently Shared on April 21, 2011 at 9:49 pm By:
Raymond DuBois Internist, Gastroenterologist, Health Executive, Physician, and Doctor
reading:Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatm http://bit.ly/go8SAV on #MDLinx #Colorectal Neoplasms
ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011
news-medical.net — “ArQule, Inc. today announced the presentation of Phase 1 results of a clinical trial among patients with metastatic colorectal cancer (CRC) treated with ARQ 197, a selective small molecule inhibitor of the c-MET receptor tyrosine kinase, in combination with irinotecan and cetuximab. ARQ 197 is under development by Daiichi Sankyo Co., Ltd. and ArQule.” View full resource at news-medical.net
Most Recently Shared on January 24, 2011 at 8:18 pm By:
Lung Cancer News: ArQule's ARQ 197 Phase 1 clinical trial results in colorectal cancer presented at ASCO 2011: A... http://bit.ly/hVC6js
Oncology Article | Colorectal Neoplasms
mdlinx.com — “EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuximab in KRAS Wild-type Metastatic Colorectal Cancer Patients” View full resource at mdlinx.com
Most Recently Shared on January 21, 2011 at 3:48 pm By:
Sandeep Pulim MD Physician, Doctor, and Health Communicator
EGFR Fluorescence In situ Hybridization Pattern of Chromosome 7 Disomy Predicts Resistance to Cetuxima... http://bit.ly/i0YXA8 #oncology
New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of Erbitux
news-medical.net — “Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today highlighted a further analysis of the large randomized Phase II OPUS study demonstrating an association between early tumor shrinkage and long-term median overall survival (OS) of more than 2 years for patients with KRAS wild-type metastatic colorectal cancer (mCRC) treated with Erbitux® (cetuximab) plus FOLFOX standard chemotherapy.” View full resource at news-medical.net
Most Recently Shared on January 19, 2011 at 2:03 pm By:
Lung Cancer News: New long-term survival data from OPUS, CRYSTAL studies demonstrate strong tumor shrinkage of E... http://bit.ly/fJ5zp4
CIG Journals - Journal Article
cigjournals.metapress.com — “CIG Journals - Journal Article” View full resource at cigjournals.metapress.com
Most Recently Shared on January 11, 2011 at 3:59 pm By:
CIG Media Group Medical Journal
Cetuximab Plus Irinotecan in Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: The LABEL Study http://tinyurl.com/65j5ycg
Colorectal cancer patients with gene mutation show better response to cancer agent
physorg.com — “Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab ...” View full resource at physorg.com
Most Recently Shared on October 26, 2010 at 9:38 pm By:
Colorectal cancer patients with gene mutation show better response to cancer agent http://bit.ly/dliF4z
Medical News: Specific KRAS Mutation Responds to Cetuximab - in Oncology/Hematology, Colon Cancer from MedPage Today
medpagetoday.com — “Patients with metastatic colorectal cancer whose tumors have a specific KRAS mutation may benefit from treatment with the monoclonal antibody cetuximab, according to a retrospective observat” View full resource at medpagetoday.com
Most Recently Shared on October 26, 2010 at 9:07 pm By:
Specific KRAS Mutation Responds to Cetuximab (CME/CE) http://bit.ly/aGaXt9
Advertisement
